TABLE. Characteristics of patients with mpox, by vaccination status — Los Angeles County, California, May 4–August 17, 2023.
| Characteristic | Vaccination status, No. (column %)* |
|||
|---|---|---|---|---|
| All (N = 56) | Fully vaccinated (n = 16) | Partially vaccinated (n = 8) | Unvaccinated (n = 32) | |
|
Median age, yrs (IQR)
|
35 (26–42)
|
37 (31–46) |
35 (25–45) |
30 (26–38) |
|
Current gender identity
| ||||
| Male |
56 (100)
|
16 (100) |
8 (100) |
32 (100) |
|
Sexual orientation
| ||||
| Gay or bisexual |
45 (80)
|
14 (88) |
6 (75) |
25 (78) |
| Heterosexual |
6 (11)
|
0 (—) |
1 (13) |
5 (16) |
| Other or unknown |
5 (9)
|
2 (13) |
1 (13) |
2 (6) |
|
Race and ethnicity
| ||||
| Black or African American, non-Hispanic |
13 (23)
|
0 (—) |
1 (13) |
12 (38) |
| White, non-Hispanic |
21 (38)
|
12 (75) |
3 (38) |
6 (19) |
| Hispanic or Latino |
18 (32)
|
3 (19) |
3 (38) |
12 (38) |
| Other |
4 (7)
|
1 (6) |
1 (13) |
2 (6) |
|
Geographic area
| ||||
| Metro LA area |
32 (57)
|
10 (63) |
6 (75) |
16 (50) |
| Outside metro LA |
24 (43)
|
6 (37) |
2 (25) |
16 (50) |
|
Persons living with HIV
|
17 (30)
|
5 (31) |
3 (38) |
9 (28) |
| CD4 >350 |
14 (82)
|
5 (100) |
3 (100) |
6 (67) |
| CD4 200–350 |
3 (18)
|
0 (—) |
0 (—) |
3 (33) |
| Not virally suppressed† |
6 (35)
|
2 (40) |
1 (33) |
3 (33) |
|
Persons who are HIV-negative
|
39 (68)
|
11 (69) |
5 (63) |
23 (72) |
| Receiving HIV PrEP§ |
26 (67)
|
11 (100) |
4 (80) |
11 (48) |
|
Persons hospitalized for mpox
|
1 (2)
|
0 (—) |
0 (—) |
1 (3) |
|
Symptoms¶
| ||||
| Pruritis |
25 (46)
|
7 (44) |
4 (57) |
14 (44) |
| Fever |
22 (40)
|
5 (31) |
2 (29) |
15 (47) |
| Chills |
16 (29)
|
3 (19) |
2 (29) |
11 (34) |
| Enlarged lymph nodes |
20 (37)
|
5 (31) |
3 (43) |
12 (38) |
| Rectal bleeding |
11 (20)
|
3 (19) |
1 (14) |
7 (22) |
| Lesions on the genital area |
36 (65)
|
10 (63) |
6 (86) |
20 (63) |
|
Received tecovirimat
|
18 (32)
|
7 (44) |
2 (25) |
9 (28) |
|
Reported contact with someone with mpox¶,** symptoms
|
7 (13)
|
1 (6) |
1 (14) |
5 (16) |
|
Reported sexual contact 3 weeks before episode date
¶,††
|
48 (87)
|
14 (88) |
6 (86) |
28 (88) |
|
Median no. of sex partners (range)
¶
,**
|
2 (0–55)
|
3 (0–10) |
2 (0–3) |
1 (0–55) |
| Reported travel outside LA county ≤3 wks before episode date ¶,†† | 13 (24) | 5 (31) | 2 (29) | 6 (19) |
Abbreviations: LA = Los Angeles; PrEP = preexposure prophylaxis.
* Some percentages might not sum to 100% because of rounding.
† Last viral load result >200 copies/mL or no viral load result reported in previous 12 months.
§ At time of mpox case interview; all persons who were HIV-negative were interviewed.
¶ Fifty-five of 56 patients were interviewed, including all who were fully vaccinated, seven out of eight who were partially vaccinated, and all who were unvaccinated.
** Three weeks before symptom onset.
†† Episode date is calculated from the symptom onset date or specimen collection date if symptom onset is unknown.